Pharmacokinetics of Anti-Rheumatic drugs Methotrexate and Tofacitinib with its metabolite M9 in Rats by UPLC-MS/MS
Er-min Gu,Lingjie Xue,Chenjian Zhou,Yang Xia,Ge-xin Dai
DOI: https://doi.org/10.2174/0109298673256258231219060950
IF: 4.74
2024-01-17
Current Medicinal Chemistry
Abstract:Background: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). The clinical efficacy and safety of an administered tofacitinib, either monotherapy or in combination with conventional synthetic disease-modifying anti-rheumatic drugs, mainly methotrexate (MTX), have been evaluated. The high plasma concentration with delayed medicine clearance may affect the liver and/or kidney functions. In this study, an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC- MS/MS) method for the quantitative analysis of methotrexate, tofacitinib, and metabolite M9 in plasma of Sprague Dawley (SD) rats was developed, and its effectiveness was validated as well. background: Referring to the relevant literatures, only one reported the simultaneous measurement of tofacitinib and methotrexate in rat plasma, but did not mention the major metabolite of tofacitinib, M9. As far as we know, it is the first research to simultaneously quantify the levels of the three analytes. Methods: Methotrexate, tofacitinib, M9 and fedratinib (internal standard, IS) were separated by gradient elution. The chromatography was performed on an Acquity BEH C18 (2.1 mm × 50 mm, 1.7 μm) column with the mobile phases of acetonitrile and 0.1% formic acid aqueous solution with different proportions at the flow rate of 0.30 mL/min. In the positive ionization mode, the analyzes were detected using a Xevo TQ-S triple quadrupole tandem mass spectrometer, with the following mass transition pairs: m/z 313.12 → 148.97 for tofacitinib, m/z 329.10 → 165.00 for M9 and m/z 455.12 → 308.05 for methotrexate. objective: The pharmacokinetic profiles of methotrexate, tofacitinib, and M9 in Sprague Dawley (SD) rat plasma were explored using a newly validated ultra-performance liquid chromatography tandem mass spectrometry (UPLC- MS/MS) method. Results: The obtained results manifested good calibration linearity over the ranges of tofacitinib at 0.1-100 ng/mL, M9 at 0.05-100 ng/mL, and methotrexate at 0.05-100 ng/mL. The lower limit of quantifications (LLOQs) of methotrexate, tofacitinib and M9 were 0.05 ng/mL, 0.1 ng/mL and 0.05 ng/mL, respectively. Intra-day and inter-day accuracy values were confirmed with a range of -6.3% to 12.7%, while intra-day and inter-- day precision values were ≤14.4%. Additionally, recoveries were greater than 86.5% for each compound without significant matrix effects. method: With rapid precipitation of the plasma proteins by acetonitrile, chromatographic separations of methotrexate, tofacitinib, M9 and fedratinib (internal standard, IS) were performed on gradient elution with acetonitrile and 0.1% formic acid aqueous solution and an Acquity BEH C18 (2.1 mm × 50 mm, 1.7 μm) column. In the positive ionization mode, the analytes were detected using a Xevo TQ-S triple quadrupole tandem mass spectrometer. Conclusion: The currently established analytical method exhibited great potential for the evaluation of plasma concentrations of methotrexate, tofacitinib and M9 simultaneously, greatly reducing the detection time, which would serve as a supplementary role in formulating dose decisions to achieve personalized treatment, identify drugs that cause adverse reactions and finally, to assess drug-drug interactions on clinical studies. result: The determination showed good calibration linearity over the ranges of tofacitinib at 0.1-100 ng/mL, M9 at 0.05-100 ng/mL and methotrexate at 0.05-100 ng/mL. The lower limit of quantifications (LLOQs) of methotrexate, tofacitinib and M9 were 0.05 ng/mL, 0.1 ng/mL and 0.05 ng/mL, respectively. Intra-day and inter-day accuracies values ranged from -6.3% to 12.7% for all analytes, while intra-day and inter-day precision was ≤14.4%. Recoveries were greater than 86.5% for each compound without significant matrix effects. conclusion: The currently established analytical method can evaluate plasma concentrations of methotrexate, tofacitinib and M9 at the same time which could reduce the patients’ waiting time, aid dose decisions to achieve personalized treatment, help to identify which drug causes adverse reactions and assess drug-drug interactions on human clinical studies.
pharmacology & pharmacy,biochemistry & molecular biology,chemistry, medicinal